Skip to content
Screener

Roivant Sciences ROIV Switzerland — Net operating losses

Similar metrics at other companies

Belden logo
BDCSwitzerland — Net Operating Loss Carryforwards
$22.38M
Immunovant, Inc. logo
IMVTSwitzerland — Net operating loss carry forwards
$279M-74.5%
Insmed logo
INSMSwitzerland — Operating loss carryforwards
$277.1M+92.0%
California Resources logo
CRCCALIFORNIA — Net operating loss carryforwards
$2B0.0%
DexCom logo
DXCMOther states — Net operating loss
$5.1M-12.1%
Belden logo
BDCOther — Net Operating Loss Carryforwards
$25.41M+215%

Other financials

Income statement

See full
Revenue$1.4M-33.5%
Operating income-$366.0M-28.5%
Net income-$189.8M+15.0%
EPS (diluted)-$0.26+21.2%

Balance sheet

See full
Cash & equivalents$77.1M-18.7%
Total debt$107.2M+7.5%
Total equity$4.2B-2.6%
Total assets$5.3B+5.4%

Cash flow

See full
Operating cash flow-$270.5M-32.4%
CapEx$419.0K-89.6%
Free cash flow-$270.9M-30.0%

Valuation

See full
Market cap$25.37B+219%
Enterprise value$25.4B+219%
P/S3,368×+3,026×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp
FCF margin-10,901%-22,382pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio16.7×-23.8×

Where this comes from

Reported directly by Roivant Sciences in its filing.

Tagged under the XBRL concept us-gaap:OperatingLossCarryforwards.

The source filing: Roivant Sciences’s 10-K, filed May 20, 2026.

Filed
May 20, 2026, 7:17 AM EDT
Fiscal year
FY2025
Accession
0001635088-26-000061

The Company has net operating losses in Switzerland, the U.S. and the U.K. in the amount of $1,512.9 million, $890.7 million and $613.4 million, respectively. The Switzerland net operating losses will expire in varying amounts between March 31, 2027 and March 31, 2032. The U.S. net operating losses can be carried forward indefinitely with utilization limited to 80% of future taxable income for tax years beginning on or after January 1, 2021, while the U.K. and other net operating losses can be carried forward indefinitely as well, with an annual limitation on utilization. The Company has $66.0 million of federal research tax credit carryforwards in the U.S., which will expire in varying amounts between March 31, 2039 and March 31, 2046. Additionally, credits of $10.8 million are related to various states and Canada.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FAQ

What is Roivant Sciences's switzerland — net operating losses?
Roivant Sciences (ROIV) reported switzerland — net operating losses of $1.51B in Q1 2026.
How has Roivant Sciences's switzerland — net operating losses changed year-over-year?
Roivant Sciences's switzerland — net operating losses decreased by 41.4% year-over-year, from $2.58B to $1.51B.
What does switzerland — net operating losses mean?
This metric quantifies the accumulated tax losses generated by the Swiss segment that can be carried forward to offset future taxable income. It serves as a significant tax asset that may reduce future cash outflows for income taxes. Investors track this to evaluate the potential for future tax shields and the historical performance volatility of the Swiss operations.

Ask your AI about Roivant Sciences's switzerland — net operating losses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude